Felix Faustus

My method is human and works on a meta level- higher than tribal analysis, to talk with it depolarises issues and brings it straight to the core of the matter. I do this just by understanding systems theory. I don't need an AI to know what I want to say, but sometimes I'll get an AI to clarify what I want to say, it doesn't take away anything from the heart of the message and the fact its coming from a human that is actually thinking all of this through and putting up my own views and methods of learning about the world.

Smoking cigarettes is nihilistic. Some people think that makes them interesting. It actually makes them evil.

A Bayesian Framing of the Immune-Complex Geometry Hypothesis This is not a claim. It is a mechanistic hypothesis with testable predictions. Start with well-accepted premises: Complement efficiently clears small, soluble immune complexes Large or persistent immune complexes are more likely to deposit in microvasculature Complement activation produces C3a, C5a, and MAC, which influence endothelial function Microvascular dysfunction can produce subtle, diffuse physiological effects None of these premises are controversial. The question is whether antigen geometry and persistence could shift systems from regime (1) to regime (2). The Geometry Hypothesis If antigen exposure is: • Transient • Low density • Fragmented Then immune complexes tend to remain: • Small • Soluble • Efficiently cleared But if antigen exposure is: • Persistent • Repeating • High-density Then antibodies may bind along extended structures, forming: • Larger immune complexes • Clustered Fc regions • Strong complement activation However, strong activation does not necessarily imply efficient clearance. Large immune complexes are: • Harder to transport • Harder to phagocytose • More likely to interact with endothelium • More likely to deposit in microvasculature This is consistent with known immune-complex disease dynamics. Why Microvasculature Matters Microvascular beds are particularly sensitive because they: • Have high surface area • Experience slow or turbulent flow • Are vulnerable to immune-complex deposition Common targets in immune-complex disease include: • Kidneys • Skin • Joints • Small vessels Two additional biologically plausible sites: Brain microvasculature Heart microvasculature Brain Large immune complexes do not typically cross the blood-brain barrier. However, they do not need to cross it to influence it. Immune-complex interaction with brain microvasculature could: • Activate complement locally • Trigger endothelial signaling • Alter permeability dynamics This does not imply BBB breakdown. It implies potential modulation of barrier behavior, which could produce: • Subtle • Conditional • Diffuse effects Heart The heart may be more directly exposed. Unlike the brain, the heart lacks a comparable barrier. It has: • Dense microvasculature • High metabolic demand • Sensitivity to perfusion changes Even small microvascular disturbances can produce: • Transient perfusion effects • Electrical sensitivity • Functional variability Cardiology already recognizes this class of phenomena: Coronary microvascular dysfunction Normal large arteries Small-vessel dysfunction Bayesian Interpretation This hypothesis predicts: Not catastrophic effects Not universal harm Not large signals But: Subtle Conditional Subgroup-dependent Long-tail signals Which are precisely the kinds of signals that: • Appear intermittently • Disappear in aggregates • Are difficult to detect with standard epidemiology Testable Predictions If this model is correct, we might expect: • Complement activation markers elevated in subsets • Evidence of immune-complex formation in circulation • Microvascular function differences in subgroups • Heterogeneous outcomes rather than uniform effects Falsifiability This model weakens if: • No evidence of persistent immune complexes • No complement activation differences • No microvascular signatures • No subgroup-specific signals Bayesian Bottom Line This is not an argument from certainty. It is a shift in generative model: From: Uniform exposure Uniform clearance Uniform outcomes To: Geometry-dependent exposure Conditional clearance Subgroup-dependent outcomes The system doesn’t need to fail. The regime just needs to shift. And small regime shifts often produce long-tail signals rather than headline effects.

A Bayesian Framing of the Immune-Complex Geometry Hypothesis This is not a claim. It is a mechanistic hypothesis with testable predictions. Start with well-accepted premises: Complement efficiently clears small, soluble immune complexes Large or persistent immune complexes are more likely to deposit in microvasculature Complement activation produces C3a, C5a, and MAC, which influence endothelial function Microvascular dysfunction can produce subtle, diffuse physiological effects None of these premises are controversial. The question is whether antigen geometry and persistence could shift systems from regime (1) to regime (2). The Geometry Hypothesis If antigen exposure is: • Transient • Low density • Fragmented Then immune complexes tend to remain: • Small • Soluble • Efficiently cleared But if antigen exposure is: • Persistent • Repeating • High-density Then antibodies may bind along extended structures, forming: • Larger immune complexes • Clustered Fc regions • Strong complement activation However, strong activation does not necessarily imply efficient clearance. Large immune complexes are: • Harder to transport • Harder to phagocytose • More likely to interact with endothelium • More likely to deposit in microvasculature This is consistent with known immune-complex disease dynamics. Why Microvasculature Matters Microvascular beds are particularly sensitive because they: • Have high surface area • Experience slow or turbulent flow • Are vulnerable to immune-complex deposition Common targets in immune-complex disease include: • Kidneys • Skin • Joints • Small vessels Two additional biologically plausible sites: Brain microvasculature Heart microvasculature Brain Large immune complexes do not typically cross the blood-brain barrier. However, they do not need to cross it to influence it. Immune-complex interaction with brain microvasculature could: • Activate complement locally • Trigger endothelial signaling • Alter permeability dynamics This does not imply BBB breakdown. It implies potential modulation of barrier behavior, which could produce: • Subtle • Conditional • Diffuse effects Heart The heart may be more directly exposed. Unlike the brain, the heart lacks a comparable barrier. It has: • Dense microvasculature • High metabolic demand • Sensitivity to perfusion changes Even small microvascular disturbances can produce: • Transient perfusion effects • Electrical sensitivity • Functional variability Cardiology already recognizes this class of phenomena: Coronary microvascular dysfunction Normal large arteries Small-vessel dysfunction Bayesian Interpretation This hypothesis predicts: Not catastrophic effects Not universal harm Not large signals But: Subtle Conditional Subgroup-dependent Long-tail signals Which are precisely the kinds of signals that: • Appear intermittently • Disappear in aggregates • Are difficult to detect with standard epidemiology Testable Predictions If this model is correct, we might expect: • Complement activation markers elevated in subsets • Evidence of immune-complex formation in circulation • Microvascular function differences in subgroups • Heterogeneous outcomes rather than uniform effects Falsifiability This model weakens if: • No evidence of persistent immune complexes • No complement activation differences • No microvascular signatures • No subgroup-specific signals Bayesian Bottom Line This is not an argument from certainty. It is a shift in generative model: From: Uniform exposure Uniform clearance Uniform outcomes To: Geometry-dependent exposure Conditional clearance Subgroup-dependent outcomes The system doesn’t need to fail. The regime just needs to shift. And small regime shifts often produce long-tail signals rather than headline effects.

What will it take for the masses to see this?